INTRODUCTION
The day after the conference "nҀ3 Fatty Acids: Recommendations for Therapeutics and Prevention," a workshop was held at the Institute of Human Nutrition, Columbia University, New York, NY (22 May 2005) . Present at the workshop were Sharon R Akabas, Jan Breslow, Yvon Carpentier, Richard J Deckelbaum, Esther Granot, Joseph Hibbeln, Craig Jensen, and Penny Kris-Etherton. Susan Carlson and Philip Calder submitted their summaries before the workshop but were not in attendance. All participants had been briefed before the workshop and apprised of the workshop goals and objectives. The workshop objectives were to consider and summarize the strength of the data on positive (or negative) effects of nҀ3 fatty acids as follows:
1) To assess which single nҀ3 fatty acids [␣-linolenic acid (ALA), eicosapentaenoic acid (EPA), or docosahexaenoic acid (DHA)] or combinations might be responsible for specific biological effects in different areas of health and disease.
2) Where the data, studies, and consensus permit, to either corroborate or set a recommendation for specific intakes of nҀ3 fatty acids for each topic reviewed.
3) Wherever possible, to distinguish between prevention and treatment of the condition when making recommendations.
4) Where the data are insufficient or too disparate to permit setting a recommendation, to identify in general terms the studies needed for such recommendations to be set.
Each participant was supplied a grid for organizing and summarizing data on specific nҀ3 fatty acids; for pregnancy and infant development, we added arachidonic acid (AA). A sample empty grid is shown in Figure 1 .
The workshop participants concluded that most work to date has not sufficiently distinguished between the specific nҀ3 fatty acids, especially between DHA and EPA, nor in many studies have background intakes of nҀ6 fatty acids been adequately controlled.
Each area was summarized by using 2 general categories: 1) current knowledge for which a general consensus exists, and 2) gaps and recommendations for research and policy. The workshop concluded with a summary of the general conclusions that are relevant to all areas of nҀ3 fatty acids and health. References for the summaries below can be found in the articles included in the supplement.
PREGNANCY

Current knowledge for which a general consensus exists
• High fish oil consumption is associated with an increase in gestational length and may reduce the rates of postpartum depression.
• Women should have 100 -300 mg DHA/d.
Gaps and recommendations for research and policy
• More work should be done to assess whether these doses are associated with any increased bleeding.
• More extensive dose-response studies should be conducted.
• Further assessment of specific effects of DHA and EPA should be conducted on neuropsychological function, immune response, and rates of infection in the infant.
INFANTS Current knowledge for which a general consensus exists
• High intake ratios of EPA to DHA can lead to a decreased growth rate.
• Current levels of DHA:AA (1.4:1 to 2:1) are beneficial for the visual and cognitive development of low-birth-weight infants and likely also normal-birth-weight infants.
Gaps and recommendations for research and policy
• The role of ALA is poorly understood and should be further examined, but ALA likely cannot substitute for DHA.
• Dose responses of AA and DHA need to be more fully characterized.
• Whether DHA is beneficial for immune and allergic response in older infants should be examined.
CARDIOVASCULAR DISEASE
Current knowledge for which a general consensus on EPA and DHA exists
• Reduced overall mortality after onset of cardiovascular disease.
• Reduced sudden death and arrhythmias, primarily in secondary prevention trials.
• Reduced blood triacylglycerol concentrations with higher doses.
• May slightly increase LDL, but the increase is not clinically significant.
• Limited effect associated with increased ALA.
Gaps and recommendations for research and policy
• Dose-response data for EPA and DHA are limited and should be studied.
• Some data from small clinical trials suggest that DHA alone is similar to or better than a combination of EPA plus DHA; these studies should be replicated in larger trials.
• A large trial on the effects of nҀ3 fatty acids in the primary prevention of cardiovascular disease should be conducted.
MENTAL HEALTH
Current knowledge for which a general consensus exists
• EPA plus DHA appear to have better efficacy than either alone.
• DHA alone has not been effective.
• nҀ3 Fatty acids are likely to improve psychotic, depressive, and aggressive symptoms in severe patients.
Gaps and recommendations for research and policy
• A clear body of treatment data on effects of EPA, DHA, or both has not yet been developed for either schizophrenia, depressive, or aggressive disorders; thus, recommendations should be cautious.
• Dose-response data and primary prevention trials are lacking.
AGING: DEMENTIA AND MACULAR DEGENERATION
Current knowledge for which a general consensus exists
• Increased fish and DHA intake are protective against cognitive decline.
• Fish consumption and DHA are associated with a reduced risk of developing Alzheimer disease.
• DHA may improve mental function and reduce aggression in patients with dementia.
• Consuming fish and low linoleic acid is associated with reduced risk of age-related macular degeneration.
Gaps and recommendations for research and policy
• Dose-response and primary prevention studies for both dementia and age-related macular degeneration are needed.
METABOLIC SYNDROME Current knowledge for which a general consensus exists
• To improve insulin sensitivity, nҀ3 fatty acids are more useful in prevention than in treatment.
• EPA plus DHA effectively lowers blood triacylglycerol concentrations.
• High doses tend to decrease small, dense LDL concentrations and may improve insulin sensitivity.
• Inclusion of nҀ3 fatty acids should be considered along with other lifestyle interventions such as exercise, diet, and medication.
Gaps and recommendations for research and policy
• Dose-response studies should be examined, especially because different individuals seem to be affected differently by nҀ3 fatty acids.
• An upper level of intake for benefit needs to be established.
• A primary intervention or prevention trial should be conducted.
INFLAMMATORY AND IMMUNE RESPONSE
• For rheumatoid arthritis, there is a proven therapeutic benefit of EPA plus DHA. All studies that monitored use of nonsteroidal antiinflammatory agents reported a significant reduction in use, and nҀ3 fatty acids reduce requirements for corticosteroids.
• Although evidence is weaker for treatment of Crohn disease and psoriasis, nҀ3 fatty acids prolong remission in Crohn disease and reduce the requirement for corticosteroids in both conditions. • ␣-Linolenic acid is not antiinflammatory at intakes 10 g/d.
Gaps and recommendations for research and policy
• Dose-response and primary prevention studies are needed in all areas of inflammatory and immune response.
• Some evidence exists that nҀ3 fatty acids are therapeutic for childhood asthma; more studies are needed. • There is contradictory or no evidence that nҀ3 fatty acids are therapeutic in the treatment of ulcerative colitis, systemic lupus erythematosus, or adult asthma; more studies are needed.
GENERAL CONCLUSIONS RELEVANT TO ALL AREAS
Current knowledge for which a general consensus exists
• Preformed long-chain nҀ3 fatty acids, derived from marine or algal sources, are more efficient biologically than are plant-derived nҀ3 ALA.
• The efficiency of conversion of plant-derived ALA to EPA and DHA, where it has been shown to be beneficial, is dependent in large part on the nҀ6 fatty acid content of the diet.
Gaps and recommendations for research advancing policy
• In almost every area, data are insufficient to make recommendations for intake of specific nҀ3 fatty acids, eg, EPA versus DHA versus EPA ѿ DHA combined.
• To develop more specific recommendations, more data will be needed that compare dose-response relations for both EPA and DHA.
• Biological effects of nҀ3 fatty acids will be better elucidated when tissue concentrations of each nҀ3 fatty acid are measured. Wherever possible, tissue concentrations should FIGURE 1. A sample grid used by the workshop participants to organize and summarize data on specific nҀ3 fatty acids. ALA, ␣-linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; AA, arachidonic acid. be used to develop dose-response curves. Determining the appropriate tissue still requires more research, but at this time, plasma concentrations can be used as a reliable surrogate when the specific tissue level of interest cannot be obtained.
• The intake of nҀ6 fatty acids may markedly affect the nҀ3 fatty acid intake required to achieve a desirable tissue nҀ3 fatty acid level. Future studies should consider that higher nҀ6 fatty acid intakes may lead to higher nҀ3 fatty acid requirements to achieve desired biological effects.
• Intervention trials at a given dosage or form of an nҀ3 fatty acid are not necessarily going to have the same effect as more prolonged or lifelong intakes of nҀ3 fatty acids. Therefore, intakes required to prevent a specific disease may be different from intakes required to treat a disease, and research data should be interpreted with this in mind.
• Data are lacking for primary prevention in almost every health area, and secondary prevention trials do not necessarily predict the usefulness of nҀ3 fatty acids for primary prevention.
• National public health initiatives to increase nҀ3 fatty acid consumption are needed; the working group believes that data are currently sufficient to indicate that intake of nҀ3 fatty acids is suboptimal, and a national and international initiative should be launched to shift nҀ3 fatty acid intake upward.
• Cross-disciplinary initiatives should be encouraged when studying the effects of nҀ3 fatty acids (eg, if a mental health study is being performed, include endpoints relevant to cardiovascular disease).
